Abstract
The characterization of the first selective orally active and brain-penetrant β3-adrenoceptor agonist, SR58611A (amibegron), has opened new possibilities for exploring the involvement of this receptor in stress-related disorders. By using a battery of tests measuring a wide range of anxiety-related behaviors in rodents, including the mouse defense test battery, the elevated plus-maze, social interaction, stress-induced hyperthermia, four-plate, and punished drinking tests, we demonstrated for the first time that the stimulation of the β3 receptor by SR58611A resulted in robust anxiolytic-like effects, with minimal active doses ranging from 0.3 to 10 mg/kg p.o., depending on the procedure. These effects paralleled those obtained with the prototypical benzodiazepine anxiolytic diazepam or chlordiazepoxide. Moreover, when SR58611A was tested in acute or chronic models of depression in rodents, such as the forced-swimming and the chronic mild stress tests, it produced antidepressant-like effects, which were comparable in terms of the magnitude of the effects to those of the antidepressant fluoxetine or imipramine. Supporting these behavioral data, SR58611A modified spontaneous sleep parameters in a manner comparable to that observed with fluoxetine. Importantly, SR58611A was devoid of side effects related to cognition (as shown in the Morris water maze and object recognition tasks), motor activity (in the rotarod), alcohol interaction, or physical dependence. Antagonism studies using pharmacological tools targeting a variety of neurotransmitters involved in anxiety and depression and the use of mice lacking the β3 adrenoceptor suggested that these effects of SR58611A are mediated by β3 adrenoceptors. Taken as a whole, these findings indicate that the pharmacological stimulation of β3 adrenoceptors may represent an innovative approach for the treatment of anxiety and depressive disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bakalian MJ, Fernstrom JD (1990). Effects of L-tryptophan and other amino acids on electroencephalographic sleep in the rat. Brain Res 528: 300–307.
Bianchetti A, Manara L (1990). In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol 100: 831–839.
Blanchard RJ, Griebel G, Henrie JA, Blanchard DC (1997). Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci Biobehav Rev 21: 783–789.
Boissier JR, Simon P, Aron C (1968). A new method for rapid screening of minor tranquillizers in mice. Eur J Pharmacol 4: 145–151.
Cecchi M, Khoshbouei H, Javors M, Morilak DA (2002). Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience 112: 13–21.
Claustre Y, Leonetti M, Santucci V, Bougault I, Desvignes C, Rouquier L et al (Submitted). Effects of the β3-adrenoreceptor agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuropsychopharmacology.
Cruz AP, Frei F, Graeff FG (1994). Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49: 171–176.
Cryan JF, Valentino RJ, Lucki I (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced-swimming test. Neurosci Biobehav Rev 29: 547–569.
Ennaceur A, Delacour J (1988). A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31: 47–59.
File ES, Cheeta S, Akanezi C (2001). Diazepam and nicotine increase social interaction in gerbils: a test for anxiolytic action. Brain Res 888: 311–313.
Gorman AL, Dunn AJ (1993). Beta-adrenergic receptors are involved in stress-related behavioral changes. Pharmacol Biochem Behav 45: 1–7.
Griebel G, Sanger D (1999). The mouse defense test battery: an experimental model of different emotional states. In: Haug M, Whalen RE (eds). Animal Models of Human Emotion and Cognition. Am Psychol Association: Washington, DC, pp 75–85.
Griebel G, Sanger D, Perrault G (1997). Genetic differences in the Mouse Defense test Battery. Aggress Behav 23: 19–31.
Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B et al (2002b). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370–6375.
Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P et al (2002a). 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301: 333–345.
Gurguis GN, Blakeley JE, Antai-Otong D, Vo SP, Orsulak PJ, Petty F et al (1999). Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome. J Psychiatr Res 33: 309–322.
Hancock AA, Marsh CL (1985). Agonist interactions with beta-adrenergic receptors following chronic administration of desipramine or the atypical antidepressants, iprindole and mianserin. J Recept Res 5: 311–334.
Holoubek G, Noldner M, Treiber K, Muller WE (2004). Effect of chronic antidepressant treatment on beta-receptor coupled signal transduction cascade. Which effect matters most? Pharmacopsychiatry 37 (Suppl 2): S113–S119.
Lenard NR, Gettys TW, Dunn AJ (2003). Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther 305: 653–659.
Manara L, Bianchetti A (1990). Further heterogeneity of the beta-adrenoceptor. The phenylethanolaminotetralines: new selective agonists for atypical beta-adrenoceptors. Trends Pharmacol Sci 11: 229–230.
Manier DH, Gillespie DD, Sulser F (1989). Characterization of the inducible serotonin-sensitive dihydroalprenolol binding sites with low affinity for isoproterenol. Neuropsychopharmacology 2: 89–95.
Miczek KA (1979). A new test for aggression in rats without aversive stimulation: differential effects of D-amphetamine and cocaine. Psychopharmacology 60: 253–259.
Millan M (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110: 135–370.
Morris R (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.
Pellow S, Chopin P, File SE, Briley M (1985). Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149–167.
Porsolt R, Le Pichon M, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730–732.
Ressler KJ, Nemeroff CB (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12: 2–19.
Revelli JP, Preitner F, Samec S, Muniesa P, Kuehne F, Boss O et al (1997). Targeted gene disruption reveals a leptin-independent role for the mouse beta3-adrenoceptor in the regulation of body composition. J Clin Invest 100: 1098–1106.
Rodriguez M, Carillon C, Coquerel A, Le Fur G, Ferrara P, Caput D et al (1995). Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Brain Res Mol Brain Res 29: 369–375.
Salomé N, Stemmelin J, Cohen C, Griebel G (2006). Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 83: 533–539.
Sanchez C, Gruca P, Papp M (2003). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14: 465–470.
Sharpley AL, Cowen PJ (1995). Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37: 85–98.
Simiand J, Keane PE, Guitard J, Langlois X, Gonalons N, Martin P et al (1992). Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol 219: 193–201.
Stahl SM, Beer MS, Hacker SA, Poat JA, Iversen L (1987). Beta-1 and beta-2-adrenoceptor regulation in rat nervous system by chronic treatment with desipramine and beta-adrenoceptor agonists. Psychopharmacol Bull 23: 473–475.
Strosberg AD (1997). Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37: 421–450.
Strosberg AD, Pietri-Rouxel A (1996). Function and regulation of the beta 3-adrenoceptor. Trends Pharmacol Sci 17: 373–381.
Summers RJ, Papaioannou M, Harris S, Evans BA (1995). Expression of beta 3-adrenoceptor mRNA in rat brain. Br J Pharmacol 116: 2547–2548.
Vanover KE, Robledo S, Huber M, Carter RB (1999). Pharmacological evaluation of a modified conflict procedure: punished drinking in non-water-deprived rats. Psychopharmacology 145: 333–341.
Vogel JR, Beer B, Clody DE (1971). A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21: 1–7.
Willner P, Muscat R, Papp M (1992). Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16: 525–534.
Zethof TJ, Van der Heyden JA, Tolboom JT, Olivier B (1995). Stress-induced hyperthermia as a putative anxiety model. Eur J Pharmacol 294: 125–135.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stemmelin, J., Cohen, C., Terranova, JP. et al. Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders. Neuropsychopharmacol 33, 574–587 (2008). https://doi.org/10.1038/sj.npp.1301424
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301424
Keywords
This article is cited by
-
Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice
Scientific Reports (2022)
-
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model
Alzheimer's Research & Therapy (2021)
-
Activation of β3-adrenoceptor increases the number of readily releasable glutamatergic vesicle via activating Ca2+/calmodulin/MLCK/myosin II pathway in the prefrontal cortex of juvenile rats
Scientific Reports (2021)
-
Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder
Psychopharmacology (2020)
-
β1-adrenergic receptors mediate plasma acyl-ghrelin elevation and depressive-like behavior induced by chronic psychosocial stress
Neuropsychopharmacology (2019)
